Skip to content
FrontierPicks

Covered

EVMN · Evommune

Conviction · Low · not more likely to lead the S&P 500 over the next three months

Event-driven Catalyst · Oncology & immunology

Note written ·

The last three months

Down 48.5% since the close; the S&P 500 is down 9.4% over the same sessions. Figures in the note can cover a different window.

EVMN daily closes from 24 August 2026 to 20 November 2026, last $7.04, with its price line set under the older rule: a daily close above $8.62; 50-day average $7.13 on 20 November 2026. 24 August 2026: $13.67; 50-day average $14.7625 August 2026: $13.79; 50-day average $14.6426 August 2026: $14.11; 50-day average $14.5027 August 2026: $13.48; 50-day average $14.3728 August 2026: $13.23; 50-day average $14.2231 August 2026: $12.66; 50-day average $14.051 September 2026: $12.48; 50-day average $13.852 September 2026: $12.48; 50-day average $13.613 September 2026: $12.00; 50-day average $13.384 September 2026: $12.27; 50-day average $13.148 September 2026: $13.08; 50-day average $12.909 September 2026: $10.84; 50-day average $12.8210 September 2026: $10.56; 50-day average $12.7611 September 2026: $10.54; 50-day average $12.7214 September 2026: $10.43; 50-day average $12.6615 September 2026: $9.99; 50-day average $12.6216 September 2026: $9.37; 50-day average $12.5417 September 2026: $9.37; 50-day average $12.4618 September 2026: $9.65; 50-day average $12.3821 September 2026: $9.45; 50-day average $12.3122 September 2026: $9.60; 50-day average $12.2623 September 2026: $8.77; 50-day average $12.1924 September 2026: $8.80; 50-day average $12.1225 September 2026: $8.49; 50-day average $12.0628 September 2026: $8.39; 50-day average $11.9829 September 2026: $8.35; 50-day average $11.9230 September 2026: $8.26; 50-day average $11.841 October 2026: $7.21; 50-day average $11.752 October 2026: $6.92; 50-day average $11.675 October 2026: $6.65; 50-day average $11.576 October 2026: $6.61; 50-day average $11.487 October 2026: $6.22; 50-day average $11.378 October 2026: $6.41; 50-day average $11.289 October 2026: $6.25; 50-day average $11.1812 October 2026: $6.05; 50-day average $11.0813 October 2026: $5.88; 50-day average $10.9614 October 2026: $5.77; 50-day average $10.8115 October 2026: $5.93; 50-day average $10.6716 October 2026: $5.17; 50-day average $10.5119 October 2026: $5.27; 50-day average $10.3320 October 2026: $5.38; 50-day average $10.1621 October 2026: $5.17; 50-day average $9.9822 October 2026: $5.21; 50-day average $9.8023 October 2026: $5.10; 50-day average $9.6226 October 2026: $5.13; 50-day average $9.4327 October 2026: $5.16; 50-day average $9.2528 October 2026: $6.31; 50-day average $9.0929 October 2026: $6.81; 50-day average $8.9330 October 2026: $6.73; 50-day average $8.792 November 2026: $6.01; 50-day average $8.633 November 2026: $5.94; 50-day average $8.474 November 2026: $6.04; 50-day average $8.325 November 2026: $6.37; 50-day average $8.166 November 2026: $6.65; 50-day average $8.039 November 2026: $7.65; 50-day average $7.9210 November 2026: $7.84; 50-day average $7.8211 November 2026: $8.62; 50-day average $7.7412 November 2026: $8.02; 50-day average $7.6513 November 2026: $7.63; 50-day average $7.5716 November 2026: $7.10; 50-day average $7.4617 November 2026: $7.02; 50-day average $7.3418 November 2026: $6.88; 50-day average $7.2619 November 2026: $7.24; 50-day average $7.2020 November 2026: $7.04; 50-day average $7.13

Daily closes, to . Red: the note's price line under the older rule, a daily close above $8.62, set on 18 November 2026. The pale line is the 50-day average, $7.13 on .

Price line

A daily close above $8.62, the 11 November 2026 close before the third-quarter report, which would show buying outweighing the dilution and the wait until 2027 data. An acquisition offer or a partnership bringing in non-dilutive cash would also show the shares leading.

A price line, set under the rules before kill lines became business results on 20 November 2026. It stays until the note's next read replaces it; a close through it only makes the note due for a fresh read.

Research onlyNot in the portfolio.

The portfolio's record →

The business · as of

Evommune is a clinical-stage biotech developing drugs for chronic inflammatory diseases: EVO301 for atopic dermatitis and ulcerative colitis, EVO756 for migraine, and the licensed oral degrader EVO570. It sells no product and earns money only from partner payments. It reported no revenue in the quarter to 30 September 2026 and a net loss of $30.9 million.

What is changing, and what follows · as of

What is changing now
On 4 November 2026 Evommune licensed EVO570 from Hinova for $30 million upfront. On 5 November 2026 it announced a $30 million share sale at $6.04. Both followed EVO756's Phase 2b failures in June and September 2026.
What follows for the company
Third-quarter R&D expense rose to $24.6 million and G&A to $8.8 million. Cash and investments were $262.3 million at 30 September 2026, with a runway the company puts into the second half of 2029.
What follows for its customers, suppliers and competitors
EVO301 competes in atopic dermatitis with Dupixent from Regeneron (REGN) and Sanofi (SNY). EVO570 enters the VAV1 degrader field where Novartis (NVS) is already active.

What the price assumes · as of

At the 17 November 2026 close (filed inputs to 12 November 2026), market value is $290 million, P/B 1.2 and free-cash-flow yield −31.4%; P/E is not meaningful and enterprise value is not available. The price values the company slightly above its $251 million of equity. It holds only if the four-quarter cash burn of $91 million is funded without deeper dilution until the 2027 data.

Key figures from the filings · Health Care

Quarter to 30 September 2026, filed 12 November 2026; valuation at the 20 November 2026 close

The last six quarters

Revenue over the six quarters to 30 September 2026, from the company's filings with the SEC, the latest filed 12 November 2026.
Revenue, latest quarter ($M)
0.0
Revenue, change on a year (%)
−100.0
Operating margin (%)
−133.3
Free cash flow, four quarters ($M)
−91.0
Free-cash-flow yield (%)
−31.3
All filed numbers

What Evommune reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .

Results by quarter Each quarter with the day its figures were first filed, and the day of a later filing that changed them; no gross margin is reported
Quarter to Revenue ($M) On a year (%) Operating margin (%)
first filed 0.0 −100.0 —
first filed 0.0 — —
first filed 0.0 −100.0 —
first filed 0.0 — —
first filed 10.0 — −133.3
first filed 0.0 — —
Income Quarter to 30 September 2026, filed 12 November 2026
Pre-tax income ($M) Not reported
Net income ($M) four quarters: −113 −30.9
Diluted shares, change on a year (%) against the quarter to 30 September 2025 +2251.2
Cash flow Four quarters to 30 September 2026, filed 12 November 2026
Operating cash flow ($M) −90.4
Capital spending ($M) 0.6
Free cash flow ($M) −91.0
Balance sheet At 30 September 2026, filed 12 November 2026
Cash and short-term investments ($M) 169
Debt ($M) Not available
Net cash, cash less debt ($M) Not available
Deferred revenue ($M) Not reported
Backlog, orders not yet delivered ($M) Not reported
Receivables ($M) Not reported
Inventory ($M) Not reported
Shareholders' equity ($M) 251
Valuation At the 20 November 2026 close, filed figures to 12 November 2026
Market value ($M) 291
Enterprise value, market value plus net debt ($M) Not available
Enterprise value to sales (×) Not available
Enterprise value to operating income (×) Not available
Price to earnings (×) Not meaningful
Price to book value (×) 1.2
Free-cash-flow yield (%) −31.3

Short interest (FINRA, settled 30 October 2026, published 10 November 2026): 8.2% of shares outstanding sold short, 3.0 days of average trading to cover, −4.1% since the previous report.

Insiders' open-market trades SEC Form 4, by trade date
Window Bought Sold
90 days Not available yet Not available yet
12 months Not available yet Not available yet

Linked companies · as of

Competitors:
REGN, SNY, NVS

The thesis

Evommune's shares are more likely to lag the S&P 500 over the next three months. In 2026 its lead drug, EVO756, failed its main goal in two Phase 2b trials. The remaining programs report no new patient data until the second half of 2027. Meanwhile the company loses about $31 million a quarter and has just sold new shares at $6.04. The next scheduled check is the fourth-quarter and full-year report, expected around March 2027.

The business case now rests on three programs that are years from approval. EVO301 is an IL-18 binding protein fusion for atopic dermatitis. EVO570 is an oral VAV1 degrader licensed in November 2026. EVO756 is now being tested in migraine. The company's 12 November 2026 release lists no patient readout from any of them before the second half of 2027. Until then the price depends on cash, dilution and sentiment toward small biotech, with no trial result to move it. The rating is Low because nothing scheduled before February 2027 is likely to change how the market values the pipeline.

Bullish and bearish views on Evommune, Inc.

The bull case on Evommune, Inc. (EVMN), in brief: EVO301 posted strong early efficacy. The bear case: the lead drug failed twice in 2026.

Bull case

  • EVO301 posted strong early efficacy. Phase 2a data presented at the EADV dermatology congress in October 2026 showed a 55% drop from baseline in the eczema severity score (EASI) at week 12, against 22% on placebo (p<0.01). No treatment-related serious or severe adverse events were reported (company release, 12 November 2026).
  • The cash runway reaches the second half of 2029. Cash, cash equivalents and investments were $262.3 million at 30 September 2026, according to the 12 November 2026 release, before a private placement of about $30 million announced on 5 November 2026.
  • The shares trade close to book value. At the 17 November 2026 close (filed inputs to 12 November 2026), market value was $290 million and price to book 1.2, against filed equity of $251 million ($6.08 a share) at 30 September 2026.
  • Two covering analysts still see upside. Needham kept a Buy rating on 15 November 2026 and cut its target from $28 to $25. Leerink Partners kept a bullish rating and a $22 target on 16 November 2026.

Bear case

  • The lead drug failed twice in 2026. EVO756 missed its primary endpoint in a 160-patient Phase 2b trial in chronic spontaneous urticaria (top-line results, 29 June 2026). It then missed in atopic dermatitis in September 2026, and the company dropped that indication (12 November 2026 release).
  • There is no patient data before late 2027. EVO756 migraine top-line results are due in the second half of 2027. The EVO301 Phase 2b in atopic dermatitis starts in mid-2027. EVO570 begins Phase 1 in the first quarter of 2027 (12 November 2026 release).
  • Losses and dilution are both rising. Net loss was $30.9 million in the third quarter of 2026, against $12.5 million a year earlier. G&A expense rose to $8.8 million from $3.7 million. The 5 November 2026 placement sold 4,966,889 shares at $6.04, against a February 2026 financing at $27.88 a share.
  • There is no revenue. The company reported no revenue in 2026 through 30 September 2026, against $10.0 million from the Maruho EVO756 collaboration in the third quarter of 2025 (10-Q filed 12 November 2026).
  • Management incentives were reset lower. On 13 November 2026 the board repriced options on 3,692,840 shares, originally priced at $16.00–26.77, to $7.63. It also approved cash retention awards for three officers, with the second installment tied to a $15.00 share price (8-K, 17 November 2026).

Price setup · as of

The shares closed at $7.02 on 17 November 2026, 78.9% below the 52-week intraday high of $33.20 set on 10 February 2026. The 3-month change is −53.2%, measured from the 19 August 2026 close of $15.01. The September atopic dermatitis failure falls inside that window. The 52-week closing low is $5.10, set on 23 October 2026.

After that low, the shares rallied through the EADV data and the 4 November 2026 Hinova license to close at $8.62 on 11 November 2026. They then fell for four straight sessions after the 12 November 2026 results and the option repricing. The last close is below the 50-day moving average of $7.34 and far below the 200-day average of $17.03 (adjusted daily closes, as of 17 November 2026).

The $6.04 placement price sits between the October low and the last close. A common market view is that biotech stocks trading near cash tend to recover. Across US stocks, no reliable effect has been found so far for what follows a fall of this size.

Catalysts ahead

  • ~15 March 2027 (est.): Fourth-quarter and full-year 2026 results. Shows whether quarterly losses stay near $31 million and whether the runway guidance into the second half of 2029 holds without another share sale.
  • ~31 March 2027 (est.): EVO570 Phase 1 and EVO301 ulcerative colitis Phase 2 trial starts, guided for the first quarter of 2027. Starting on time would show the newly licensed and remaining programs are moving; a delay would push the 2027 data dates further out.
  • ~31 December 2027 (est.): EVO756 Phase 2b migraine top-line data, guided for the second half of 2027. The next efficacy readout for EVO756 after two Phase 2b failures, and the first patient data that could change the value placed on the pipeline.

What it trades with · as of

In 2026 the shares moved mainly on the company's own trial readouts: 29 June 2026 (urticaria failure), September (atopic dermatitis failure), October (EVO301 data at EADV) and November (EVO570 license and financing). With no readout due before the second half of 2027, the shares are likely to follow sentiment toward small, loss-making immunology biotechs and funding conditions more than company news.

EVO301 targets atopic dermatitis, the market Dupixent from Regeneron (REGN) and Sanofi (SNY) leads. EVO570 targets the same VAV1 molecular glue approach as Novartis (NVS), according to Fierce Biotech on 5 November 2026. Moves in this kind of stock can be large: the standard deviation of 63-session returns across liquid US stocks was 27% in 2026.

Caveats

  • Options on 3,692,840 shares were repriced to $7.63 on 13 November 2026. Exercising them before the end of a 12-month retention period requires paying the original exercise price as a premium. Form 8-K filed 17 November 2026 · as of
  • Officer cash retention awards pay half after one year. The second half requires a share price of at least $15.00 by the second anniversary, or a change in control. Form 8-K filed 17 November 2026 · as of
The evidence, claim by claim (8)
  1. EVO756 missed its primary endpoint in a 160-patient Phase 2b trial in chronic spontaneous urticaria, and development in that indication was stopped. Evommune top-line results release, 29 June 2026 · as of
  2. EVO756 missed its primary endpoint in a Phase 2b trial in atopic dermatitis in September 2026, and development in that indication was stopped. Evommune third-quarter 2026 results release · as of
  3. EVO301 reduced EASI by 55% from baseline at week 12, against 22% on placebo (p<0.01), in Phase 2a atopic dermatitis data presented at EADV in October 2026. Evommune third-quarter 2026 results release · as of
  4. Third-quarter 2026 net loss was $30.9 million ($0.85 a share), against $12.5 million a year earlier; there was no revenue, against $10.0 million a year earlier. Form 10-Q for the third quarter of 2026 · as of
  5. Cash, cash equivalents and investments were $262.3 million at 30 September 2026, with a cash runway the company guides into the second half of 2029. Evommune third-quarter 2026 results release · as of
  6. Evommune licensed EVO570 from Hinova for $20 million in cash and $10 million in pre-funded warrants upfront, with milestones and tiered royalties to follow. Form 8-K filed 4 November 2026 · as of
  7. A private placement of 4,966,889 shares at $6.04 a share raised about $30 million in gross proceeds. Evommune release, 5 November 2026 · as of
  8. Needham cut its Evommune target from $28 to $25 and kept a Buy rating; Leerink Partners kept a $22 target on 16 November 2026. Needham note 15 November 2026; Leerink Partners note 16 November 2026 · as of

Sources

Related · shared themes

Every buy and sale, with its reason, is published in the portfolio feed. Follow the portfolio feed → Follow @frontierpicks on X